Investor Presentation - First Six Months of 2021
7
Investor presentation
First six months of 2021
Solid diabetes sales growth across all regions in International
Operations
Reported diabetes sales and growth per IO geography
Diabetes value market share and share of growth in IO
DKK
billion
30
13%
25
46%
20
20
Market
■Insulin I GLP-1 Growth at CER
share
NN market share
NN share of growth
180%
Geographical area
120%
11%
15
6%
36%
I
10
I
13%
60%
19%
68%
5
2%
69%
10%
10%
0
ΙΟ
EMEA
China
ROW
0%
May
2019
Note: The share of growth development in 2021 is impacted by COVID-19 stocking in 2020 and the price reductions on oral-anti diabetics following Volume-Based Procurement (VBP) in China
Source: IQVIA MAT, May 2021 (Spot rate)
IO: International operations; NN: Novo Nordisk; pp: Percentage points; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; Row: Rest of World
Novo Nordisk®
91.7%
22.5%
23.9%
Market share +1.4-pp vs. 2020
May
May
2020
2021View entire presentation